AstraZeneca (US Rights for Toprol-XL) Overview

  • Status

  • Acquired/​Merged

  • Latest Deal Type

  • M&A

  • Financing Rounds

  • 3

AstraZeneca (US Rights for Toprol-XL) General Information

Description

Portfolio of distribution rights for a beta-blocker medicine. The portfolio consists of U.S. distribution rights for the branded and authorized generic drug designed for the treatment of hypertension (high blood pressure), angina (chest pain) and heart failure.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Melinta Therapeutics
Primary Office
  • 2 Kingdom Street
  • London W2 6BD
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AstraZeneca (US Rights for Toprol-XL) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AstraZeneca (US Rights for Toprol-XL)‘s full profile, request access.

Request a free trial

AstraZeneca (US Rights for Toprol-XL) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AstraZeneca (US Rights for Toprol-XL)‘s full profile, request access.

Request a free trial